EUVIMEDEUVIMED entdecken
Fall-Kontroll-Studie

Ultra-High Performance Liquid Chromatography-Mass Spectrometry-based Serum Metabolomics for Early Diagnosis of Refractory Tumor-induced Osteomalacia: A Case-control Study

Xiang Li, Yiyi Gong iD, Qi Zhang, Xiaolin Ni, Qianqian Pang, Yue Chi, Ruizhi Jiajue, Lijia Cui, Xu Jiang, Ou Wang, Xiaoping Xing, Yan Jiang iD und 2 weitere

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgad034 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Xiang Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases…. Hauptthemen laut MEDLINE: Metabolome, Metabolomics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Beijing Municipal Natural Science Foundation, National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Nearly 20% patients with tumor-induced osteomalacia (TIO) experienced recurrence or nonrecovery after surgery. Serum fibroblast growth factor 23 and phosphate concentrations are not sufficient for prognosis in such cases. Despite its importance for understanding of prognosis and underlying pathogenesis, the alteration of systemic metabolism in refractory TIO remains unclear.

Objective

We aimed to find the metabolomic characteristics of refractory TIO and establish a novel predictive model for early discriminating refractory TIO based on their serum metabolomics. Design and setting Cross-section study for comparison of metabolomic profile between TIO and normal control and longitudinal study for identifying prognostic model.

Methods

Based on liquid chromatography-tandem mass spectrometry, we analyzed the global metabolomes of preoperative sera from 86 samples (32 TIO recovery patients, 11 nonremission patients, and 43 matched controls). Statistical analyses, pathway enrichment, and receiver operating characteristic analysis were performed to identified and evaluate potential markers.

Results

Sparse partial least squares discriminant analysis indicated a clear separation of metabolomic profiles between healthy controls (HC) and TIO patients. The serum metabolites altered in different prognostic groups. L-pipecolic acid, 2-dodecylbenzenesulfonic acid, and 2-deoxygalactopyranose were the top 3 metabolites that were significantly perturbed. A combination of L-pipecolic acid and 2-dodecylbenzenesulfonic acid demonstrated a high-performance panel for TIO prognosis evaluated by random forest algorithm (area under the curve = 0.921, 95% CI, 0.787-0.995).

Conclusions

We investigate the global metabolomes of refractory TIO and identify potential prognostic biomarkers preliminarily. A high sensitivity and specificity panel were identified as promising discriminating predictors, which need to be verified in more patients. This work may demonstrate novel insights into TIO prognosis and pathogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetabolomeMetabolomicsBiomarkersLongitudinal StudiesHumansMass SpectrometryChromatography, High Pressure LiquidCase-Control StudiesEarly DiagnosisBenzenesulfonatesOsteomalaciaParaneoplastic Syndromes

Stichwörter der Autor:innen

biomarkermetabolomicsprognosisrefractorytumor-induced osteomalacia

Substanzen

Biomarkersdodecylbenzenesulfonic acidBenzenesulfonates

Autor:innen und Institutionen

  • Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sc…
  • Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
  • State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.
  • Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.

ORCID-Profile: Yiyi Gong, Yan Jiang, Mei Li, Weibo Xia

Förderung

  • Beijing Municipal Natural Science Foundation
  • National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences
  • National Key R&D Program of China

Zitieren

APA

Li, X., Gong, Y., Zhang, Q., Ni, X., Pang, Q., Chi, Y., Jiajue, R., Cui, L., Jiang, X., Wang, O., Xing, X., Jiang, Y., Li, M., & Xia, W. (2023). Ultra-High Performance Liquid Chromatography-Mass Spectrometry-based Serum Metabolomics for Early Diagnosis of Refractory Tumor-induced Osteomalacia: A Case-control Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad034

Vancouver

Li X, Gong Y, Zhang Q, Ni X, Pang Q, Chi Y, et al. Ultra-High Performance Liquid Chromatography-Mass Spectrometry-based Serum Metabolomics for Early Diagnosis of Refractory Tumor-induced Osteomalacia: A Case-control Study. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad034

BibTeX
@article{Li2023,
  author = {Li, Xiang and Gong, Yiyi and Zhang, Qi and Ni, Xiaolin and Pang, Qianqian and Chi, Yue and Jiajue, Ruizhi and Cui, Lijia and Jiang, Xu and Wang, Ou and Xing, Xiaoping and Jiang, Yan and Li, Mei and Xia, Weibo},
  title = {Ultra-High Performance Liquid Chromatography-Mass Spectrometry-based Serum Metabolomics for Early Diagnosis of Refractory Tumor-induced Osteomalacia: A Case-control Study},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgad034}
}
Kostenlos starten →